The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Published 2020 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
Authors
Keywords
SARS-CoV-2, COVID-19, JAK/STAT pathway, Ruxolitinib, Cytokine storm
Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2020-06-20
DOI
10.1016/j.cytogfr.2020.06.013

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.